Identificación de los estados fenológicos del crecimiento en olivo

La adecuada identificación de los estados fenológicos de las plantas es muy importante para la caracterización varietal, así como para la conducción de las plantaciones(tratamientos, aclareos, etc). Las claves fenológicas utilizadas hasta ahora, como las clásicas de Fleckinger para los frutales, no cumplen los requisitos que actualmente se consideran necesarios: que describan el ciclo completo del desarrollo (y no sólo la floración), que utilicen códigos numéricos (para que puedan ser utilizados en bases de datos) y que sirvan para todas las especies de plantas cultivadas y malas hierbas. La escala BBCH sí que cumple estos requisitos. Se trata de una escala decimal de 2 dígitos, de los cuales el primero (de 0 a 9) se refiere a un estado principal de desarrolloy el segundo (también de 0 a 9) a un estado secundario dentro del principal. La escala BBCH ya ha sido utilizada en España para la identificación de los estados de crecimiento de varias especies leñosas (cítricos, granado, níspero). En el caso del olivo, la identificación de los estados de crecimiento se ha realizado en el contexto de los trabajos de identificación, caracterización y evaluación de variedades autóctonas de olivo en la Comunidad Valenciana. Se describen un total de 32 estados fenológicos agrupados en 7 estados principales: desarrollo de las yemas, desarrollo de las hojas, desarrollo de los brotes, desarrollo de las inflorescencias, floración, desarrollo de los frutos y maduración

Discrete Nonholonomic Lagrangian Systems on Lie Groupoids

This paper studies the construction of geometric integrators for nonholonomic systems. We derive the nonholonomic discrete Euler-Lagrange equations in a setting which permits to deduce geometric integrators for continuous nonholonomic systems (reduced or not). The formalism is given in terms of Lie groupoids, specifying a discrete Lagrangian and a constraint submanifold on it. Additionally, it is necessary to fix a vector subbundle of the Lie algebroid associated to the Lie groupoid. We also discuss the existence of nonholonomic evolution operators in terms of the discrete nonholonomic Legendre transformations and in terms of adequate decompositions of the prolongation of the Lie groupoid. The characterization of the reversibility of the evolution operator and the discrete nonholonomic momentum equation are also considered. Finally, we illustrate with several classical examples the wide range of application of the theory (the discrete nonholonomic constrained particle, the Suslov system, the Chaplygin sleigh, the Veselova system, the rolling ball on a rotating table and the two wheeled planar mobile robot).Comment: 45 page

Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study

<p>Abstract</p> <p>Background</p> <p>Ritonavir-boosted saquinavir (SQVr) is nowadays regarded as an alternative antiretroviral drug probably due to several drawbacks, such as its high pill burden, twice daily dosing and the requirement of 200 mg ritonavir when given at the current standard 1000/100 mg bid dosing. Several once-daily SQVr dosing schemes have been studied with the 200 mg SQV old formulations, trying to overcome some of these disadvantages. SQV 500 mg strength tablets became available at the end of 2005, thus facilitating a once-daily regimen with fewer pills, although there is very limited experience with this formulation yet.</p> <p>Methods</p> <p>Prospective, multicentre study in which efficacy, safety and pharmacokinetics of a regimen of once-daily SQVr 1500/100 mg plus 2 NRTIs were evaluated under routine clinical care conditions in either antiretroviral-naïve patients or in those with no previous history of antiretroviral treatments and/or genotypic resistance tests suggesting SQV resistance. Plasma SQV trough levels were measured by HPLV-UV.</p> <p>Results</p> <p>Five hundred and fourteen caucasian patients were included (47.2% coinfected with hepatitis C and/or B virus; 7.8% with cirrhosis). Efficacy at 52 weeks (plasma RNA-HIV <50 copies/ml) was 67.7% (CI₉₅: 63.6 - 71.7%) by intention-to-treat, and 92.2% (CI₉₅: 89.8 - 94.6%) by on-treatment analysis. The reasons for failure were: dropout or loss to follow-up (18.4%), virological failure (7.8%), adverse events (3.1%), and other reasons (4.6%). The high rate of dropout may be explained by an enrollement and follow-up under routine clinical care condition, and a population with a significant number of drug users. The median SQV Cmin (n = 49) was 295 ng/ml (range, 53-2172). The only variable associated with virological failure in the multivariate analysis was adherence (OR: 3.36; CI95, 1.51-7.46, p = 0.003).</p> <p>Conclusions</p> <p>Our results suggests that SQVr (1500/100 mg) once-daily plus 2 NRTIs is an effective regimen, without severe clinical adverse events or hepatotoxicity, scarce lipid changes, and no interactions with methadone. All these factors and its once-daily administration suggest this regimen as an appropriate option in patients with no SQV resistance-associated mutations.</p

Detection of He I λ10830\lambda10830 \AA{} absorption on HD 189733 b with CARMENES high-resolution transmission spectroscopy

We present three transit observations of HD 189733 b obtained with the high-resolution spectrograph CARMENES at Calar Alto. A strong absorption signal is detected in the near-infrared He I triplet at 10830 \AA{} in all three transits. During mid-transit, the mean absorption level is $0.88\pm0.04$ % measured in a $\pm$10 km s$^{-1}$ range at a net blueshift of $-3.5\pm0.4$ km s$^{-1}$ (10829.84--10830.57 \AA{}). The absorption signal exhibits radial velocities of $+6.5\pm3.1$ km s$^{-1}$ and $-12.6\pm1.0$ km s$^{-1}$ during ingress and egress, respectively; measured in the planetary rest frame. We show that stellar activity related pseudo-signals interfere with the planetary atmospheric absorption signal. They could contribute as much as 80% of the observed signal and might also affect the radial velocity signature, but pseudo-signals are very unlikely to explain the entire signal. The observed line ratio between the two unresolved and the third line of the He I triplet is $2.8\pm0.2$, which strongly deviates from the value expected for an optically thin atmospheres. When interpreted in terms of absorption in the planetary atmosphere, this favors a compact helium atmosphere with an extent of only 0.2 planetary radii and a substantial column density on the order of $4\times 10^{12}$ cm$^{-2}$. The observed radial velocities can be understood either in terms of atmospheric circulation with equatorial superrotation or as a sign of an asymmetric atmospheric component of evaporating material. We detect no clear signature of ongoing evaporation, like pre- or post-transit absorption, which could indicate material beyond the planetary Roche lobe, or radial velocities in excess of the escape velocity. These findings do not contradict planetary evaporation, but only show that the detected helium absorption in HD 189733 b does not trace the atmospheric layers that show pronounced escape signatures.Comment: 13 pages, 12 figures, accepted for publication in A&

Radon (222Rn) outgassing in San Juan volcanic tubes during the Cumbre Vieja eruption 2021, and preliminary values in the newly volcanic tubes.

During the eruption at Cumbre Vieja ridge (La Palma, Canary Islands, 2021) a radon (222Rn) detector (CORENTIUM Pro alpha particles counter) was emplaced inside the Las Palomas lava tube (San Juan eruption, 1949). In addition, a CO2 meter logger was emplaced to determine relationships between the 2021 eruption and radon plus CO2 inner fluxes. There is a geostructural relationship between the 1949 and 2021 eruptions, probably connected by a previous fault, shown the volcanic vents¿ alignment trending NW-SE. In October 2021, the radon and CO2 loggers were moved to the upper part of the lava tube, in the San Juan volcanic vent (Llano del Banco hollow dyke). Once the eruption ended (in early 2022) both loggers were placed in one newly formed lava tube, and data will be collected in February 2023. Preliminary results show daily average radon values ranging between 2 - 9 Bq/m3, although sporadic peaks of about 270 and 650 Bq/m3 were recorded related to volcano-tectonic earthquakes and volcanic intensity. In general, basaltic eruptions of alkaline affinity show low radon values due to the low concentration in the magma body of uranium and related chemical elements (Th, Ra, etc.). Geochemical analysis of emitted lavas shows a U concentration of about 1 to 5 ppm (g/g) and Th 9.5 ppm. Summer values of Rn increased up to 3 KBq/m3, related to the climate conditions instead of volcanic activity

El Curso Mamíferos del Pirineo, 2012-2018

[No abstract available

Multicenter prospective clinical study to evaluate children short-term neurodevelopmental outcome in congenital heart disease (children NEURO-HEART) : study protocol

Altres ajuts: RETICS funded by the PN 2018-2021 (Spain).Congenital heart disease (CHD) is the most prevalent congenital malformation affecting 1 in 100 newborns. While advances in early diagnosis and postnatal management have increased survival in CHD children, worrying long-term outcomes, particularly neurodevelopmental disability, have emerged as a key prognostic factor in the counseling of these pregnancies. Eligible participants are women presenting at 20 to < 37 weeks of gestation carrying a fetus with CHD. Maternal/neonatal recordings are performed at regular intervals, from the fetal period to 24 months of age, and include: placental and fetal hemodynamics, fetal brain magnetic resonance imaging (MRI), functional echocardiography, cerebral oxymetry, electroencephalography and serum neurological and cardiac biomarkers. Neurodevelopmental assessment is planned at 12 months of age using the ages and stages questionnaire (ASQ) and at 24 months of age with the Bayley-III test. Target recruitment is at least 150 cases classified in three groups according to three main severe CHD groups: transposition of great arteries (TGA), Tetralogy of Fallot (TOF) and Left Ventricular Outflow Tract Obstruction (LVOTO). The results of NEURO-HEART study will provide the most comprehensive knowledge until date of children's neurologic prognosis in CHD and will have the potential for developing future clinical decisive tools and improving preventive strategies in CHD. , on 4th December 2016 (retrospectively registered)

Memoria del Mapa Geológico de España, Escala 1:50.000, 2ª Serie, 1ª Edición, (MAGNA), Hoja Nº 512, Cifuentes

Peer reviewe

Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial

IMPORTANCE: Secretory phospholipase A2(sPLA2) generates bioactive phospholipid products implicated in atherosclerosis. The sPLA2inhibitor varespladib has favorable effects on lipid and inflammatory markers; however, its effect on cardiovascular outcomes is unknown. OBJECTIVE: To determine the effects of sPLA2inhibition with varespladib on cardiovascular outcomes. DESIGN, SETTING, AND PARTICIPANTS: A double-blind, randomized, multicenter trial at 362 academic and community hospitals in Europe, Australia, New Zealand, India, and North America of 5145 patients randomized within 96 hours of presentation of an acute coronary syndrome (ACS) to either varespladib (n = 2572) or placebo (n = 2573) with enrollment between June 1, 2010, and March 7, 2012 (study termination on March 9, 2012). INTERVENTIONS: Participants were randomized to receive varespladib (500 mg) or placebo daily for 16 weeks, in addition to atorvastatin and other established therapies. MAIN OUTCOMES AND MEASURES: The primary efficacy measurewas a composite of cardiovascular mortality, nonfatal myocardial infarction (MI), nonfatal stroke, or unstable angina with evidence of ischemia requiring hospitalization at 16 weeks. Six-month survival status was also evaluated. RESULTS: At a prespecified interim analysis, including 212 primary end point events, the independent data and safety monitoring board recommended termination of the trial for futility and possible harm. The primary end point occurred in 136 patients (6.1%) treated with varespladib compared with 109 patients (5.1%) treated with placebo (hazard ratio [HR], 1.25; 95%CI, 0.97-1.61; log-rank P = .08). Varespladib was associated with a greater risk of MI (78 [3.4%] vs 47 [2.2%]; HR, 1.66; 95%CI, 1.16-2.39; log-rank P = .005). The composite secondary end point of cardiovascular mortality, MI, and stroke was observed in 107 patients (4.6%) in the varespladib group and 79 patients (3.8%) in the placebo group (HR, 1.36; 95% CI, 1.02-1.82; P = .04). CONCLUSIONS AND RELEVANCE: In patients with recent ACS, varespladib did not reduce the risk of recurrent cardiovascular events and significantly increased the risk of MI. The sPLA2inhibition with varespladib may be harmful and is not a useful strategy to reduce adverse cardiovascular outcomes after ACS. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01130246. Copyright 2014 American Medical Association. All rights reserved